4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM), 97.0%, 5g

(R)-tert-Butyl (1-oxopropan-2-yl)carbamate, 95.0%, 10g

Cyclopropanamine, 1-(3,4-dimethoxyphenyl)-, 98%, 1g

Monomethacryloxypropyl functional poldimethylsiloxanes methoxypropyl terminated symmetric 8-12cSt, 100g

TERT-BUTYL 7-(HYDROXYMETHYL)-5-OXA-2-AZASPIRO[3.4]OCTANE-2-CARBOXYLATE, 95.0%, 1g

1-(tert-Butoxycarbonyl)-3,3-difluoropiperidine-4-carboxylic acid, 95.0%, 250mg

4'-(Methylsulfonyl)-2,2' : 6',2"-terpyridine, 95.0%, 2g

(E)-(4-(3-Ethoxy-3-oxoprop-1-en-1-yl)phenyl)boronic acid, 98%, 1g

4-Bromo-5-methylpyridin-2(1H)-one, 97%, 1g

Methyl 3-(4-ethoxyphenyl)-3-oxopropanoate, 98%, 5g

Methyl4-bromo-3-chloro-5-(trifluoromethoxy)benzoate, 98%, 25g

m-C-tri(CH2-PEG1-NHS ester), 100mg

Matraz receptor con revestimiento de PUR, 500 ml, 1 unidad